TY - JOUR
T1 - Breast cancer risk associated with estrogen exposure and truncating mutation location in BRCA1/2 carriers
AU - Lecarpentier, Julie
AU - Noguès, Catherine
AU - Mouret-Fourme, Emmanuelle
AU - Buecher, Bruno
AU - Gauthier-Villars, Marion
AU - Stoppa-Lyonnet, Dominique
AU - Bonadona, Valèrie
AU - Fricker, Jean Pierre
AU - Berthet, Pascaline
AU - Caron, Olivier
AU - Coupier, Isabelle
AU - Pujol, Pascal
AU - Faivre, Laurence
AU - Gesta, Paul
AU - Eisinger, François
AU - Mari, Véronique
AU - Gladieff, Laurence
AU - Lortholary, Alain
AU - Luporsi, Elisabeth
AU - Leroux, Dominique
AU - Venat-Bouvet, Laurence
AU - Maugard, Christine M.
AU - Colas, Chrystelle
AU - Tinat, Julie
AU - Lasset, Christine
AU - Andrieu, Nadine
N1 - Publisher Copyright:
© 2015 AACR.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Background: Mutations in BRCA1/2 confer a high risk of breast cancer, but literature values of this risk vary. A genotype-phenotype correlation has been found in both genes, and the effect of reproductive factors differs according to mutation location. Therefore, we hypothesize that such a variation may exist for other factors related to estrogen exposure. Methods: We used a weighted Cox regression model to assess variation in breast cancer risk with these factors using location of mutation in homogeneous breast cancer risk region of BRCA1/2 in the GENEPSO study. Results: We found that late age at menarche reduced breast cancer risk by 31%and thatamong BRCA1 carriers, a long or a short menstrual cycle increased risk (by 65% and 73%, respectively). Among premenopausal women, overweight was associated with a 45% decrease in risk whereas underweight was associated with an increased risk (HR, 2.40). A natural menopause, mainly after age 50, was associated with a high breast cancer risk (HR, 2.46), and a significant interaction between menopause status and the location of mutations was found leading up to 10% variation in absolute risk according to the age at menopause. Conclusions: As observed in the general population, a late menarche, a long or a short menstrual cycle, over-or underweight, and being postmenopausal were associated with breast cancer risk in BRCA1/2 carriers. The association with the menopause was observed only when the mutation was located in the "high-risk" zones. Impact: Taking into account modifier factors, location of mutation might be important for the clinical management of BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev; 24(4); 698-707.
AB - Background: Mutations in BRCA1/2 confer a high risk of breast cancer, but literature values of this risk vary. A genotype-phenotype correlation has been found in both genes, and the effect of reproductive factors differs according to mutation location. Therefore, we hypothesize that such a variation may exist for other factors related to estrogen exposure. Methods: We used a weighted Cox regression model to assess variation in breast cancer risk with these factors using location of mutation in homogeneous breast cancer risk region of BRCA1/2 in the GENEPSO study. Results: We found that late age at menarche reduced breast cancer risk by 31%and thatamong BRCA1 carriers, a long or a short menstrual cycle increased risk (by 65% and 73%, respectively). Among premenopausal women, overweight was associated with a 45% decrease in risk whereas underweight was associated with an increased risk (HR, 2.40). A natural menopause, mainly after age 50, was associated with a high breast cancer risk (HR, 2.46), and a significant interaction between menopause status and the location of mutations was found leading up to 10% variation in absolute risk according to the age at menopause. Conclusions: As observed in the general population, a late menarche, a long or a short menstrual cycle, over-or underweight, and being postmenopausal were associated with breast cancer risk in BRCA1/2 carriers. The association with the menopause was observed only when the mutation was located in the "high-risk" zones. Impact: Taking into account modifier factors, location of mutation might be important for the clinical management of BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev; 24(4); 698-707.
UR - http://www.scopus.com/inward/record.url?scp=84927942946&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-14-0884
DO - 10.1158/1055-9965.EPI-14-0884
M3 - Article
C2 - 25613119
AN - SCOPUS:84927942946
SN - 1055-9965
VL - 24
SP - 698
EP - 707
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 4
ER -